biostudies-literatureVoskens CDeutsche Forschungsgemeinschaft49-53https://www.ebi.ac.uk/biostudies/studies/S-EPMC9763232biostudies-literatureUnknown72(1)<h4>Objective</h4>Ulcerative colitis (UC) is a chronic, debilitating immune-mediated disease driven by disturbed mucosal homeostasis, with an excess of intestinal effector T cells and an insufficient expansion of mucosal regulatory T cells (Tregs). We here report on the successful adoptive transfer of autologous, ex vivo expanded Tregs in a patient with refractory UC and associated primary sclerosing cholangitis (PSC), for which effective therapy is currently not available.<h4>Design</h4>The patient received a single infusion of 1×10⁶ autologous, ex vivo expanded, polyclonal Tregs per kilogram of body weight, and the clinical, biochemical, endoscopic and histological responses were assessed 4 and 12 weeks after adoptive Treg transfer.<h4>Results</h4>The patient showed clinical, GutAutologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis.PMC9763232KFO257 (Project 08) and TRR241 (Project C04)Wiesinger MSchnoy EKummer MSiegmund BStoica DHartmann AHackstein HVitali FGanslmayer MRath TWunder JKnott HAtreya RNeurath MFZundler SSchuler GVoskens CBerking CSchuler-Thurner BRosenberg MfalseAutologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis.<h4>Objective</h4>Ulcerative colitis (UC) is a chronic, debilitating immune-mediated disease driven by disturbed mucosal homeostasis, with an excess of intestinal effector T cells and an insufficient expansion of mucosal regulatory T cells (Tregs). We here report on the successful adoptive transfer of autologous, ex vivo expanded Tregs in a patient with refractory UC and associated primary sclerosing cholangitis (PSC), for which effective therapy is currently not available.<h4>Design</h4>The patient received a single infusion of 1×10⁶ autologous, ex vivo expanded, polyclonal Tregs per kilogram of body weight, and the clinical, biochemical, endoscopic and histological responses were assessed 4 and 12 weeks after adoptive Treg transfer.<h4>Results</h4>The patient showed clinical, 2023-01-01T00:00:00Z2023 Jan2026-06-08T06:50:05.367Z2026-06-08T03:14:30.709ZS-EPMC97632323542865710.1136/gutjnl-2022-327075